Evidence map›Paper›PMID 40236955›Full record

ArticleBiomaterials research2025

Physicochemical Properties and Efficacy of Poloxamer Bone Wax on Hemostasis at the Bone-Amputation Site.

Dae Hyung Lee, Miri Kim, Yeji Choi, Mi Hee Lee, Jong-Chul Park

Abstract read
In one paragraph

Article in Biomaterials research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dae Hyung LeeAdvanced Medical Device R&D Center, HansBiomed Co. Ltd., Seoul 05836, Republic of Korea.ORCID https://orcid.org/0000-0003-2171-4128
Miri KimAdvanced Medical Device R&D Center, HansBiomed Co. Ltd., Seoul 05836, Republic of Korea.ORCID https://orcid.org/0000-0002-8084-4902
Yeji ChoiAdvanced Medical Device R&D Center, HansBiomed Co. Ltd., Seoul 05836, Republic of Korea.
Mi Hee LeeCellbiocontrol Laboratory, Department of Medical Engineering, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
Jong-Chul ParkCellbiocontrol Laboratory, Department of Medical Engineering, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bone wax, an essential material for bone hemostasis in orthopedic, thoracic, and neurological surgeries, is defined as a substance that physically controls bleeding caused by bone fractures. Absorbable bone-wax products such as poloxamer multiblock copolymers can be topically applied, form a physical barrier, are biocompatible, and can be absorbed by/excreted from the body. However, absorbable bone waxes continue to have limited physical properties, poor bone adhesion, and low hemostatic quality. When applied to the affected area, they quickly dissolve in blood and body fluids, preventing maintenance of the physical barrier over a certain period and thereby reducing the hemostatic effect. This study introduces a new type of absorbable bone wax (OSSTOP) constructed from 2 poloxamer multiblock copolymers with different molecular weight ranges. To determine whether OSSTOP overcomes the limitations of the existing products, the physicochemical properties and efficacy of OSSTOP were compared with those of 2 existing absorbable bone-wax products, OSTENE and NOVOSEAL. The adhesive strengths, yield loads, and solubilities of the products were evaluated and compared in vitro. Hemostasis at the bone-amputation site and absorption/degradation of the products were then evaluated through animal experiments in vivo. The biological safety (cytotoxicity) of the newly developed OSSTOP was also assessed. A histological analysis confirmed superior hemostasis at the bone-amputation site and a favorable biological response after treatment with OSSTOP. We expect that OSSTOP will improve the convenience, hemostatic performance, and biocompatibility of bleeding cessation at bone-amputation sites in the clinical environment.

Identifiers

PMID40236955
PMCPMC11997309

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.